CIS Research Plays Key Role in FDA-Approved Diabetes and Weight Loss Trials

President and Director of Clinical & Regulatory Affairs, Dr. Eva Agaiby, leads groundbreaking research at Clinical Investigation Specialists, Inc.

FOR IMMEDIATE RELEASE

Gurnee, IL-  CIS Research is pleased to announce our pivotal contributions to clinical trials advancing FDA-approved treatment for patients with diabetes and obesity. Under the leadership of our President and Director of Clinical & Regulatory Affairs, Eva Agaiby, PharmD, CIS Research is continually positioned at the forefront of innovative healthcare solutions.

Clinical Investigation Specialists, Inc. has been honored to participate in trials sponsored by Novo Nordisk and Eli Lilly whose discoveries are contributing significantly to the development of GLP-1 agonist medications Ozempic/Wegovy and Mounjaro/Zepbound, respectively. These drugs have since been FDA-approved and are making a profound impact on patients' lives, demonstrating remarkable efficacy in managing diabetes and promoting weight loss.

Dr. Eva Agaiby, with her extensive expertise in clinical research, has been instrumental in overseeing these trials. Her commitment to excellence and patient care has ensured rigorous standards and ethical practices throughout the research process. Dr. Agaiby  emphasizes the clinic's specialization in diabetes and weight loss treatments, leveraging cutting-edge methodologies to deliver reliable results. Reflecting on the future of diabetes and weight loss drug research, she remains optimistic about continued advancements in therapeutic options.

CIS research is dedicated to conducting ongoing research to uncover new insights and treatments, offering hope to millions affected by these complex and prevalent health challenges.

To learn more about our clinical research team, visit Our Team.

To browse our current clinical studies, visit Current Studies.